Efficacy of trastuzumab-based therapy after disease progression on lapatinib based therapy in heavily pretreated HER2-positive metastatic breast cancer patients.

Uncu, DoganBayoglu, Ibrahim VedatArslan, Ulku YalcintasKucukoner, MehmetArtac, MehmetKoca, DoganOguz, Arzu2020-03-262020-03-2620140732-183X1527-7755https://dx.doi.org/10.1200/jco.2014.32.15_suppl.e11586https://hdl.handle.net/20.500.12395/3080850th Annual Meeting of the American-Society-of-Clinical-Oncology -- MAY 30-JUN 03, 2014 -- Chicago, IL[Abstract not Available]en10.1200/jco.2014.32.15_suppl.e11586info:eu-repo/semantics/closedAccessEfficacy of trastuzumab-based therapy after disease progression on lapatinib based therapy in heavily pretreated HER2-positive metastatic breast cancer patients.Conference Object3215WOS:000358613200080Q1